ReViral
ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an initial focus on the treatment of respiratory syncytial virus (RSV). The company’s lead product candidate, sisunatovir, is an orally administered fusion inhibitor currently being evaluated in two global Phase 2 clinical studies: one in a paediatric patient population and the other in an adult stem-cell transplant patient population. The company also has an N-protein replication inhibitor program in preclinical development.
Follow @ReViral_ltd
Today with @pfizer we are proud to announce that we have entered into a definitive agreement under which Pfizer will acquire ReViral and its #RSV Respiratory Syncytial Virus therapeutic candidates. Learn more: reviral.co.uk/investors-medi… pic.twitter.com/yqh5yFIytu
See other Therapeutics organisations
-
AKL Research & Development Ltd.'s focus is in inflammatory diseases, particularly those related to dysregulation of the innate immune system. -
Antabio is a private biopharmaceutical company developing a broad pipeline of novel antibacterial treatments focused on drug-resistant life threatening infections. ... -
To 2014 - Antikor Biopharma Limited was established in mid-2014 following the restructuring of PhotoBiotics Limited. The new Company retains ... -
Autifony Therapeutics aims to develop new drugs to treat serious disorders of the central nervous system using pioneering science
Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.
Learn moreCopyright © 2022 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.